AI-generated research brief — verify at source
Azithromycin Plus Montelukast Shows Substantially Higher Efficacy in Pediatric Mycoplasma Pneumonia
A meta-analysis of 36 randomized controlled trials found that adding montelukast sodium to azithromycin sequential therapy was associated with markedly higher overall clinical efficacy in children with Mycoplasma pneumoniae pneumonia — nearly five times the odds of clinical success compared to azithromycin alone (OR 4.75, 95% CI: 3.70–6.10). The combination also accelerated resolution of all measured symptoms, including cough, wheezing, pulmonary rales, and fever, without a statistically significant increase in adverse events.
What Was Studied
This meta-analysis evaluated whether combining montelukast sodium — a selective leukotriene receptor antagonist that reduces airway inflammation and hyperresponsiveness — with azithromycin sequential therapy produces better clinical outcomes than azithromycin sequential therapy alone in pediatric patients with Mycoplasma pneumoniae pneumonia (MPP). The primary outcomes assessed were overall clinical efficacy, the resolution time of key symptoms (cough, wheezing, pulmonary rales, and fever), and the safety profile of the combination regimen.
How It Was Studied
Researchers conducted a systematic review and meta-analysis, searching six databases — PubMed, Embase, Web of Science Core Collection, Wanfang Data, the Variant Impact Predictor database, and Chinese National Knowledge Infrastructure — from each database’s inception through November 2025. Eligible studies were randomized controlled trials enrolling pediatric patients diagnosed with MPP and comparing azithromycin sequential monotherapy against the same regimen augmented with montelukast. A total of 36 RCTs met inclusion criteria, encompassing 3,450 pediatric patients: 1,726 in the combination group and 1,724 in the azithromycin-only group.
What Was Observed
- Overall clinical efficacy was substantially higher in the combination group, with nearly five times greater odds of achieving a favorable clinical response compared to azithromycin monotherapy (OR 4.75, 95% CI: 3.70–6.10). This represents a large and statistically robust effect with a narrow confidence interval.
- Cough resolution time was shorter by an average of approximately 3.6 days in the combination group (MD = −3.63 days, 95% CI: −4.27 to −2.99), suggesting a clinically meaningful acceleration in symptom clearance.
- Pulmonary rales and wheezing also resolved more quickly with the combination regimen — pulmonary rales by approximately 2.1 days (MD = −2.06, 95% CI: −2.54 to −1.57) and wheezing by approximately 1.5 days (MD = −1.48, 95% CI: −1.82 to −1.14) — with both estimates excluding zero, indicating consistent directional benefit.
- Fever duration was reduced by approximately 1.4 days on average with combination therapy (MD = −1.43 days, 95% CI: −1.89 to −0.96), and no statistically significant difference in adverse event rates was observed between groups, suggesting an acceptable short-term tolerability profile for the combined approach.
Why This Matters
Mycoplasma pneumoniae pneumonia is a leading cause of community-acquired respiratory infections in children, and the rising prevalence of macrolide-resistant strains has created meaningful challenges for azithromycin monotherapy. These findings suggest that montelukast, by targeting airway inflammation through leukotriene receptor blockade, may address a distinct pathophysiological pathway not covered by antibiotics alone, potentially offering a practical adjunctive strategy when macrolide resistance undermines monotherapy effectiveness. The safety data from this pooled analysis also support the feasibility of this combination from a short-term risk perspective.
How to Read This Result
While the pooled effect sizes are large and directionally consistent, the predominantly single-center design and moderate methodological quality of the included trials introduce uncertainty about generalizability, and the results should be interpreted cautiously pending confirmation from large-scale, multicenter randomized trials.
Limitations
The 36 included trials were largely single-center studies with moderate methodological quality, limiting the generalizability of the findings to broader clinical settings. No large-scale, multicenter RCTs are yet available to validate the pooled estimates. Potential heterogeneity across trials and the possibility of publication bias — particularly given the predominance of studies from Chinese clinical registries — are additional sources of uncertainty that the authors acknowledge require further investigation.